Tax Season is Here! Save 15% on H&R Block Online
iconAll times are GMT -4. The time now is 07:16 PM. | Search:

» StockRants Stock Forum » Public Stock Forums » US Stock Picks » Strong Buy: RDHL (MC $150 M ) $60 M Cash ..3 Mega Drugs with Phase3 Results in 1H 2017



Reply
 
Thread Tools Search this Thread
Old 12-22-2016, 09:19 AM   Nav to Top  #1
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 251
Favorites: Aapl celg onxx
Rep Power: 106
Reputation: 36
Biohero is on a distinguished road
Default RDHL (MC $150 M ) $60 M Cash ..3 Mega Drugs with Phase3 Results in 1H 2017

RDHL is a brutally undervalued and almost unknown gem with many News coming within 6-7 months including Phase 3 Results from 2 Potential Blockbusters and NDA resubmission in early 2017 . Market Cap of around $150 Million and $60+ Million in cash makes this Biotech one of the most attractive in the Sector . This low float Stock is a gift below $10 with good News we could see $50 easily by end of next year .


Market Cap :$148 Million
Cash: $62 Million
Price: 9.70

Shares out 15 Million (50% of Shares held by Insiders alone)

New Presentation
http://files.shareholder.com/downloa...on_151216_.pdf


Upcoming Milestones Q4 2016:

Commercial asset: •Potential acquisition of certain commercial rights to GI asset currently on the market in the U.S.

1H 2017 :

RIZAPORT®(RHB-103):
•Re-submission of U.S. NDA


RHB-104:
•Second DSMB meeting for the MAP US Phase III study for Crohn’s disease, including safety and interim efficacy analysis, with evaluation of option of early stop for success for overwhelming efficacy -Q2/2017 <<<<<<<< POTENTIAL BLOCKBUSTER ..GLOBAL MARKET SIZE : $5+ BILLION


BEKINDA®(RHB-102):
•Top-line Phase III results (gastroenteritis) -mid-2017 <<<< MARKET SIZE $650+ MILLION
•Top-line Phase II results (IBS-D) -mid-2017



RHB-105 (H. pylori):
First Phase III study successfully met its primary endpoint with high statistical significance (p<0.001), confirmatory Phase III planned to be initiated H1/2017 <<<< POTENTIAL BLOCKBUSTER ..GLOBAL MARKET SIZE : $4+ Billion


Biohero is offline   Rate this post Yes | No Reply With Quote
Old 12-23-2016, 02:12 PM   Nav to Top  #2
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 251
Favorites: Aapl celg onxx
Rep Power: 106
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

More Infos about this undiscovered Goldmine

RedHill Biopharma's RHB-104: A Potential Game Changer for Crohn's Disease?
BioNap, Inc.: RedHill Biopharma's RHB-104: A Potential Game Changer for Crohn's Disease?

The opportunity for RedHill Biopharma with RHB-104 looks significant. If the Phase 3 trial is successful, I think the market will start to view RHB-104 as having peak sales in the $500-750 million range for the U.S., with potential expansion to over one billion on a global basis.
------

Dan Suesskind , Director
Mr. Suesskind, who served 31 years as CFO of Teva Pharmaceutical Industries (NYSE: TEVA) until 2008, had played a pivotal role in the strategic activities of the Israeli generic pharmaceuticals giant, including the acquisition of more than 30 companies. During that period, Teva grew from a small Israeli company with a market cap of $37 million, into a leading global company with a market cap exceeding $34 billion in 2008. Mr. Suesskind was a member of Teva’s board of directors until recently.
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 12-27-2016, 09:06 AM   Nav to Top  #3
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 251
Favorites: Aapl celg onxx
Rep Power: 106
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Great Analysis by J.Napodano he says stock should valued at $500 M ( currently around $150 M includes new shares offering)

RedHill Expects An Eventful Next Few Months
Jason Napodano Blog | RedHill Expects An Eventful Next Few Months | Talkmarkets

That being said, I believe RedHill BioPharma is worth approximately $500 million in value today. I see the most valuable asset as RHB-104 for Crohn's disease, followed by RHB-105 for H. pylori infection. Other important assets include Bekinda for gastroenteritis and IBS-D, RHB-104 for MS, and Yeliva and Mesupron in mid-stage development for various oncology indications. The company held $40.5 million in cash as of September 30, 2016, of which I'm including only $25 million into my sum-of-parts analysis. The company has no debt.
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 12-30-2016, 09:36 AM   Nav to Top  #4
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 251
Favorites: Aapl celg onxx
Rep Power: 106
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

One of the largest and oldest Insurance company in Israel ups stake in Redhill
Statement of Ownership (sc 13g)
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 01-03-2017, 08:30 AM   Nav to Top  #5
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 251
Favorites: Aapl celg onxx
Rep Power: 106
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Great News ..and stock is still brutally underpriced .GL

RedHill Biopharma Announces Exclusive U.S. Co-Promotion Agreement with Concordia for GI Drug Donnatal®

RedHill Biopharma Announces Exclusive U.S. Co-Promotion Agreement with Concordia for GI Drug Donnatal®

Dror Ben-Asher, Chief Executive Officer of RedHill, said: "We are pleased to partner with Concordia for the U.S. promotion of Donnatal®, a trusted brand among physicians for symptoms of IBS and acute enterocolitis5. With a core U.S. commercial team in place, we plan to initiate promotional activities in the U.S. in the coming months with a specialty gastrointestinal sales force. RedHill`s strategic transition into a revenue-generating, gastrointestinal-focused, specialty pharmaceutical company with commercial presence in the U.S., is planned to support potential future commercialization of our Phase III-stage potential blockbusters BEKINDA® for gastroenteritis and other GI indications, RHB-105 for H. pylori infection and RHB-104 for Crohn`s disease, if approved by FDA."
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 03-27-2017, 12:41 PM   Nav to Top  #6
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 251
Favorites: Aapl celg onxx
Rep Power: 106
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

maybe the cheapest Nasdaq Biotech you can get with 5x Phase 3 in various indications and a laughable Market cap of $85 Million and $50 Million in cash .The fair value should be at $8-10 right now for this unknown Biotech .

Latest stock market analyst ratings:

Brean Capital began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 20 price target on the stock.

Axsome Therapeutics, Inc. had its “” rating reiterated by analysts at Ladenburg Thalmann. They now have a USD 27 price target on the stock.

Cantor Fitzgerald began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 13 price target on the stock.
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 03-27-2017, 01:13 PM   Nav to Top  #7
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 251
Favorites: Aapl celg onxx
Rep Power: 106
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

ups wrong board
Biohero is offline   Rate this post Yes | No Reply With Quote
Reply

Similar Threads
Thread Thread Starter Forum Replies Last Post
Dividend: Stocks to watch in 2017 Silver US Stock Picks 1 12-29-2016 04:14 AM
Strong Buy: AYTU (MC $13 M) (Cash $15 M) MEGA Drug launch in July ($2+BILLION Market ) Biohero US Penny Stock Picks 2 11-14-2016 05:42 AM
Strong Buy: ARDM (MC $49 M / Cash $40 M) Phase 3 Results for Real Blockbuster in 2H 2016 = 1000% Biohero US Stock Picks 1 04-17-2016 11:06 PM
Strong Buy: RDHL (MC $146 M) Blockbuster Phase 3 Results in JUNE & 2x EU Approvals in Coming 4Q Biohero US Stock Picks 2 05-26-2015 04:13 PM
Strong Buy: SUPN = 2x MEGA DRUGS APPROVED // 1x BLOCKBUSTER IN P3 // LOW FLOAT 5 M = 500%++ POTEN Biohero US Stock Picks 0 12-03-2012 08:50 AM


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On